Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 57 min ago
Peer-reviewedLicence not statedFuture Oncology

Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors

  • Marc Oliva1
  • John Powderly2
  • Christophe Le Tourneau3
  • Amani Makkouk4
  • Philippe A. Cassier5
  • Maulik Patel6
  • Ki Chung7
  • Alexander Spira8
  • Amita Patnaik9
  • Wu-Chou Su10
  • Toshihiko Doi11
  • Victor Moreno12
12 more authors
  • Chia-Chi Lin13
  • Toshio Shimizu14
  • Sonali Jindal15,16
  • Padmanee Sharma15,16
  • Agostina Stradella1
  • Jaehyung Hong4
  • John Engelhardt4
  • Martha Blaney4
  • Tolga Turan4
  • Luija Wang4
  • Michael A. McDevitt4
  • A. Dimitrios Colevas17
17 affiliations
  1. 1Medical Oncology Department, Institut Català d’Oncologia L’Hospitalet, Barcelona, Spain
  2. 2Carolina BioOncology Institute, Huntersville, NC, USA
  3. 3Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, Paris, France
  4. 4AbbVie, South San Francisco, CA, USA
  5. 5Department of Medical Oncology, Centre Léon Bérard, Lyon, France
  6. 6AbbVie Inc., North Chicago, IL, USA
  7. 7Prisma Health Cancer Institute, Greenville, SC, USA
  8. 8Virginia Cancer Specialists, Fairfax, VA, USA
  9. 9The START Center for Cancer Research, San Antonio, TX, USA
  10. 10National Cheng Kung University Hospital, Tainan, Taiwan
  11. 11National Cancer Center Hospital East, Kashiwa, Japan
  12. 12START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain
  13. 13National Taiwan University Hospital, Taipei, Taiwan
  14. 14National Cancer Center Hospital, Tokyo, Japan
  15. 15Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  16. 16James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  17. 17Stanford University and Stanford Cancer Institute, Stanford, CA, USA
Read full textDOICite

Related

  1. Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
    Xinwei Wu, Danni Wang, Yangbin Shi +8
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  2. 548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors
    Ignacio Garcia-Ribas, Maloy Ghosh, Sanghamitra Bhattacharjee +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  3. 1189 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
    Justin Moser, Igor Puzanov, Hans Hammers +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. Phase 1 Study of Safety and PK With A Combination of Omeprazole and Trimetazidine for Fatty Acid Oxidation Inhibition in Patients With Advanced Solid Tumors.
    Wonyoung Choi, Jung W Chun, Sung H Sim +9
    Clinical and translational sciencePeer-reviewedCC BY-NCFull textOncologyEurope PMCPMC
  5. IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial
    Crescens Tiu, Wing Yau, Tencho Tenev +57
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{oliva2026phase,
  title = {{Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors}},
  author = {Marc Oliva and John Powderly and Christophe Le Tourneau and Amani Makkouk and Philippe A. Cassier and Maulik Patel and Ki Chung and Alexander Spira and Amita Patnaik and Wu-Chou Su and Toshihiko Doi and Victor Moreno and Chia-Chi Lin and Toshio Shimizu and Sonali Jindal and Padmanee Sharma and Agostina Stradella and Jaehyung Hong and John Engelhardt and Martha Blaney and Tolga Turan and Luija Wang and Michael A. McDevitt and A. Dimitrios Colevas},
  journal = {Future Oncology},
  year = {2026},
  month = oct,
  doi = {10.1080/14796694.2026.2736946},
  url = {https://doi.org/10.1080/14796694.2026.2736946},
}
RIS
TY  - JOUR
TI  - Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors
AU  - Marc Oliva
AU  - John Powderly
AU  - Christophe Le Tourneau
AU  - Amani Makkouk
AU  - Philippe A. Cassier
AU  - Maulik Patel
AU  - Ki Chung
AU  - Alexander Spira
AU  - Amita Patnaik
AU  - Wu-Chou Su
AU  - Toshihiko Doi
AU  - Victor Moreno
AU  - Chia-Chi Lin
AU  - Toshio Shimizu
AU  - Sonali Jindal
AU  - Padmanee Sharma
AU  - Agostina Stradella
AU  - Jaehyung Hong
AU  - John Engelhardt
AU  - Martha Blaney
AU  - Tolga Turan
AU  - Luija Wang
AU  - Michael A. McDevitt
AU  - A. Dimitrios Colevas
PY  - 2026
DA  - 2026/10/29
JO  - Future Oncology
DO  - 10.1080/14796694.2026.2736946
UR  - https://doi.org/10.1080/14796694.2026.2736946
SN  - 1479-6694
SN  - 1744-8301
ER  -